After search, choose a molecule or a kind of categories listed in the left to narrow down your filter. If you have any problems, please contact us!
Text Size:AAA

PLAUR / CD87 / uPAR Antibody, Rabbit PAb, Antigen Affinity Purified

DatasheetReviewsRelated ProductsProtocols
Human PLAUR/uPAR Antibody Product Information
Immunogen:Recombinant Human PLAUR / CD87 / uPAR protein (Catalog#10925-H08H)
Clone ID:
Ig Type:Rabbit IgG
Formulation:0.2 μm filtered solution in PBS with 5% trehalose
Preparation:Produced in rabbits immunized with purified, recombinant Human PLAUR / CD87 / uPAR (rh PLAUR / CD87 / uPAR; Catalog#10925-H08H; Q03405-1; Met 1-Arg 303). PLAUR / CD87 / uPAR specific IgG was purified by Human PLAUR / CD87 / uPAR affinity chromatography.
Human PLAUR/uPAR Antibody Usage Guide
Specificity:Human PLAUR / CD87 / uPAR
Application:ELISA, IP

ELISA: 0.1-0.2 μg/mL

This antibody can be used at 0.1-0.2 μg/mL with the appropriate secondary reagents to detect Human UPAR. The detection limit for Human UPAR is approximately 0.00975 ng/well.

IP: 4-6 μg/mg of lysate

Storage:This antibody can be stored at 2℃-8℃ for one month without detectable loss of activity. Antibody products are stable for twelve months from date of receipt when stored at -20℃ to -80℃. Preservative-Free.
Sodium azide is recommended to avoid contamination (final concentration 0.05%-0.1%). It is toxic to cells and should be disposed of properly. Avoid repeated freeze-thaw cycles.
Other PLAUR/uPAR Antibody Products
PLAUR/CD87 Background

Urokinase plasminogen activator (uPA) and/or its receptor (uPAR) are essential for metastasis, and overexpression of these molecules is strongly correlated with poor prognosis in a variety of malignant tumours. uPAR and uPA levels in both resected tumor tissue and plasma are of independent prognostic significance for patient survival in several types of human cancer. This system has classically been thought to drive tumor progression by mediating directed extracellular proteolysis on the surface of migrating or invading cells, and intervening with this proteolysis by targeting uPAR has been proposed to represent a novel approach for inhibiting tumor progression. uPAR, also known as PLAUR or CD87, has been implicated in the growth, metastasis, and angiogenesis of several solid and hemotologic malignancies. uPAR is a highly glycosylated, 55-60kDa integral membrane protein linked to the plasma membrane by a glycosylphosphatidylinositol (GPI) anchor. It is part of a cell surface system that also consists of the serine protease uPA and several specific inhibitors (plasminogen activator inhibitors 1 and 2). Additionally, the analysis of CD87 (urokinase-type plasminogen activator receptor - uPAR) expression has a potential role in the diagnostic or prognostic work-up of several hematological malignancies, particularly acute leukemia and multiple myeloma.

Human PLAUR/CD87 References
  • Romer J, et al. (2004) The urokinase receptor as a potential target in cancer therapy. Curr Pharm Des. 10(19): 2359-76.
  • Bn MC, et al. (2004) CD87 (urokinase-type plasminogen activator receptor), function and pathology in hematological disorders: a review. Leukemia. 18(3): 394-400.
  • Pillay V, et al. (2007) The urokinase plasminogen activator receptor as a gene therapy target for cancer. Trends Biotechnol. 25(1): 33-9.
  • Mazar AP. (2008) Urokinase plasminogen activator receptor choreographs multiple ligand interactions: implications for tumor progression and therapy. Clin Cancer Res. 14(18): 5649-55.
  • Product nameProduct name
    Size / Price
    Catalog: 10925-RP02-200
    List Price: 
    Price:      (You Save: )
    All information of our products is subject to change without notice. Please refer to COA enclosed in shipped package for the newest information.